Term ended Dec 1, 2023 · High confidence
Held by Hikma Pharmaceuticals USA Inc.
Filed Sep 10, 2009 as application 29/343,297 · Granted Dec 1, 2009
Base term, 14 years from grant
Today
Term ended Dec 1, 2023
2009
2026
Clock starts
Dec 1, 2009
Dec 1, 2009
Term ended
Dec 1, 2023
Dec 1, 2023
base term
after the term ends
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
14 years from grant
Base term
No maintenance fees are payable on this kind of patent.
13
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its base term, 14 years from grant, with no adjustment for prosecution delay. No maintenance fees are payable on this kind of patent. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 14 years from grant | Granted Dec 1, 2009 | Dec 1, 2023 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Computed term end | The steps above, in order | Dec 1, 2023 | High confidence |
This family
| US D588,200 | Term ended Mar 2023 | Mar 2023 |
| US 7,918,830 | In force May 2028 | May 2028 |
| Application PCT/US2008/083171 | PCT application no patent term | no patent term |
| US D595,361 | Term ended Jun 2023 | Jun 2023 |
| US D602,534 | Term ended Oct 2023 | Oct 2023 |
| US D593,613 | Term ended Jun 2023 | Jun 2023 |
| US D605,228 | this patent Dec 2023 | Dec 2023 |
| US D614,703 | Term ended Apr 2024 | Apr 2024 |
8 of 13 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 15, 2009 Reel 23235, frame 481 | Langan, Amy E.; Kruzynski, Richard J.; Kollar, John A.; Miyake, Patricia L.; Kruk, Monique L.; Wagner, Mark F. | Pharmedium Services, LLC | Assignment of Assignor's Interest |
| Dec 26, 2012 Reel 29539, frame 528 | Pharmedium Services, LLC | Bank of Montreal | Security Agreement |
| Feb 20, 2014 Reel 32301, frame 828 | Pharmedium Services, LLC | Jpmorgan Chase Bank, N.a. | Notice and Confirmation of Grant of Security Interest in Patents-First Lien |
| Feb 20, 2014 Reel 32302, frame 275 | Pharmedium Services, LLC | Credit Suisse AG | Notice and Confirmation of Grant of Security Interest in Patents - Second Lien |
| Aug 26, 2015 Reel 36477, frame 200 | Bank of Montreal | Pharmedium Services, LLC | Termination and Release of Security Interest in Patents |
| Nov 11, 2015 Reel 37097, frame 493 | Credit Suisse AG | Pharmedium Services, LLC | Termination and Release of Security Interest in Patent Rights - Second Lien |
| Nov 11, 2015 Reel 37097, frame 514 | Jpmorgan Chase Bank, N.a. | Pharmedium Services, LLC | Termination and Release of Security Interest in Patent Rights - First Lien |
| Aug 31, 2020 Reel 53646, frame 281 | Pharmedium Service, LLC | Runway Advisors, LLC | Assignment of Assignor's Interest |
| Feb 16, 2021 Reel 55270, frame 335 | Runway Advisors, LLC | Hikma Pharmaceuticals USA Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center
No maintenance fees are payable on this kind of patent, so the record carries no fee events.
Citations
55
later US patents cite this one
That is top 25% of design patents granted in 2009 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.